USA Today

Abbott Issues Safety Notification for FreeStyle Libre® Family of Readers in the U.S.

Abbott initiated a voluntary medical device correction in February to emphasize instructions for its FreeStyle Libre®, FreeStyle Libre® 14 day and FreeStyle Libre® 2 Readers in the United States due ...
MD&M East

FreeStyle Libre Lithium Batteries Catch Abbott Medical Device Correction

Abbott Laboratories has initiated a voluntary medical device correction pertaining to its FreeStyle Libre, FreeStyle Libre 14 day, and FreeStyle Libre 2 Readers, stating that a limited number of ...
Pharmabiz

Abbott initiates medical device correction for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors in the US

Abbott has initiated a medical device correction for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors in the United States after internal testing determined that some sensors may provide ...
The American Journal of Managed Care

FDA Approves Freestyle Libre CGM With 14-Day Sensor

The system was the first to allow people with diabetes to monitor blood glucose without fingersticks. Abbott’s 14-day Freestyle Libre continuous glucose monitor (CGM) has been approved by the FDA, ...
Nasdaq

Abbott's FreeStyle Libre® 3 Receives U.S. FDA Clearance - Features World's Smallest, Thinnest and Most Accurate 14-Day Glucose Sensor

The FreeStyle Libre 3 system is the most accurate 14-day continuous glucose monitor1, with readings sent directly to a smartphone every minute.2 Designed for access and affordability, the FreeStyle ...
Nasdaq

Abbott's FreeStyle Libre 2 Now Approved for Adults and Children with Diabetes in Canada, Featuring Unsurpassed 14-Day Accuracy and Optional Alarms

- FreeStyle Libre 2 system continuously measures glucose data every minute with customizable, optional real-time alarms1 to alert users when their glucose is high or low without scanning - Now for ...
EurekAlert!

New data show Abbott's FreeStyle® Libre 14 day system significantly reduces costs associated with diabetes management and complications

Cost model data published in U.S. Endocrinology show for commercially-insured people with diabetes on intensive insulin therapy, using FreeStyle Libre technology costs 60% less compared to traditional ...